DISTRIBUTION OF INCREMENTAL QALY ESTIMATES REPORTED IN HTA CONCLUSIONS IN UKRAINE (2022-2026)
Author(s)
Lidiia Tymoshenko, MSc1, Oresta Piniazhko, PhD2, Iuliia Malyshevska, MSc3, Yevheniia Ishkova, PhD2, Iryna Musiienko, MSc2, Valeriia Serediuk, MSc4.
1Expert, State expert center, Kyiv, Ukraine, 2State Expert Center of the Ministry of Health of Ukraine, Kyiv, Ukraine, 3Public enterprise “State Expert Centre of the Ministry of Health of Ukraine, Kyiv, Ukraine, 4The State Expert Center of the Ministry of Health of Ukraine, Kiev, Ukraine.
1Expert, State expert center, Kyiv, Ukraine, 2State Expert Center of the Ministry of Health of Ukraine, Kyiv, Ukraine, 3Public enterprise “State Expert Centre of the Ministry of Health of Ukraine, Kyiv, Ukraine, 4The State Expert Center of the Ministry of Health of Ukraine, Kiev, Ukraine.
OBJECTIVES: To analyse the distribution and variability of incremental QALY estimates reported in Health Technology Assessment (HTA) conclusions published in Ukraine between 2022 and 2026.
METHODS: A retrospective descriptive analysis of HTA conclusions published by the HTA Department of the State Expert Center of Ukraine was conducted. Overall, 92 HTA conclusions were reviewed. Incremental QALY results were publicly available in 69 reports covering 40 international non-proprietary names (INNs). In total, 102 incremental QALY estimates were extracted and analysed. Descriptive statistics included mean, median, standard deviation (SD), and 95% confidence interval (95% CI).
RESULTS: Incremental QALY estimates demonstrated substantial variability across technologies and clinical indications, ranging from −1.08 to 7.14 QALYs. The lowest value (−1.08) was reported for brigatinib versus alectinib in advanced non-small cell lung cancer, while the highest value (7.14) was identified for risdiplam versus best supportive care in spinal muscular atrophy type 1. The median incremental QALY gain was 0.635, indicating that in half of analysed cases the additional benefit didn`t exceed approximately two-thirds of one QALY. The mean value was 1.35 (SD = 1.76), exceeding the median and suggesting a positively skewed distribution influenced by a limited number of technologies associated with high QALY gains. The 95% CI for the mean ranged from 1.00 to 1.70. Overall, moderate QALY gains were observed for most interventions, while substantially higher gains were reported only for a limited number of interventions, particularly in rare diseases.
CONCLUSIONS: Incremental QALY estimates reported in HTA conclusions in Ukraine varied considerably across therapeutic areas and technologies. While most interventions were associated with gains below one QALY, several therapies demonstrated larger health benefits. These findings may support interpretation of QALY outcomes in reimbursement and health policy decision-making.
METHODS: A retrospective descriptive analysis of HTA conclusions published by the HTA Department of the State Expert Center of Ukraine was conducted. Overall, 92 HTA conclusions were reviewed. Incremental QALY results were publicly available in 69 reports covering 40 international non-proprietary names (INNs). In total, 102 incremental QALY estimates were extracted and analysed. Descriptive statistics included mean, median, standard deviation (SD), and 95% confidence interval (95% CI).
RESULTS: Incremental QALY estimates demonstrated substantial variability across technologies and clinical indications, ranging from −1.08 to 7.14 QALYs. The lowest value (−1.08) was reported for brigatinib versus alectinib in advanced non-small cell lung cancer, while the highest value (7.14) was identified for risdiplam versus best supportive care in spinal muscular atrophy type 1. The median incremental QALY gain was 0.635, indicating that in half of analysed cases the additional benefit didn`t exceed approximately two-thirds of one QALY. The mean value was 1.35 (SD = 1.76), exceeding the median and suggesting a positively skewed distribution influenced by a limited number of technologies associated with high QALY gains. The 95% CI for the mean ranged from 1.00 to 1.70. Overall, moderate QALY gains were observed for most interventions, while substantially higher gains were reported only for a limited number of interventions, particularly in rare diseases.
CONCLUSIONS: Incremental QALY estimates reported in HTA conclusions in Ukraine varied considerably across therapeutic areas and technologies. While most interventions were associated with gains below one QALY, several therapies demonstrated larger health benefits. These findings may support interpretation of QALY outcomes in reimbursement and health policy decision-making.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
HTA62
Topic
Health Policy & Regulatory, Health Technology Assessment, Methodological & Statistical Research
Topic Subcategory
Decision & Deliberative Processes, Value Frameworks & Dossier Format
Disease
No Additional Disease & Conditions/Specialized Treatment Areas